Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer

Strahlentherapie und Onkologie

Volumn 187, Issue 3, 2011, Pages 183-190

  Hentschel, Bettina ^a,c   Oehler, Wolfgang ^a   Straufß, Dirk ^a   Ulrich, Andreas ^b   Malich, Ansgar ^b  

^a Sudharz Krankenhaus Nordhausen   (Germany)

^b Department of Radiology   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Definition of prostate CTV; IMRT; MRI; Prostate cancer

Indexed keywords

ACCURACY; AGED; ARTICLE; CLINICAL TARGET VOLUME; COMPUTER ASSISTED TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PROSTATE CANCER; PROSTATE VOLUME; RADIOLOGICAL PARAMETERS; SEMINAL VESICLE; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; CANCER INVASION; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; IMAGE PROCESSING; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SEMINAL VESICLES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 79955666005     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2179-1     Document Type: Article

References (33)

1. Beyersdorff D, Tamoorian K, Knösel T, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR 2005;185:1214-20.
2. Cahlon O, Zelefsky M, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330-7.
3. Daisne JF, Sibomana M, Bol A, et al. Evaluation of a multimodality image (CT,MRI and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother. Oncol 2003;69:237-45. (Pubitemid 37485997)
4. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154: 131-8.
5. D'Amico AV, Whittington R, Malkowicz SB, et al. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 1996;14:1770-7.
6. Diaz A, Roach M, Marquez L, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;30:323-9. (Pubitemid 24309734)
7. Dolezel M, Odrazka M, Vakulikova J, et al. Dose escalation in prostate radiotherapy up to 82Gy using simultaneous integrated boost. Strahlenther Onkol 2010;186:197-202.
8. Eade T, Hanlon A, Horwitz E, et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007; 68:682-9. (Pubitemid 46818746)
9. Fransson A, Andreo P, Potter R. Aspects of MR image distortions in radiotherapy treatment planning. Strahlenther Onkol 2001;177:59-73. (Pubitemid 32162659)
10. Geets X, Daisne JF, Arcangeli S, et al. Inter-observer variability in the delineation of pharyngo-laryngeal tumor, parotid glands and cervical spinal cord: Comparison between CT-scans and MRI. Radiother Oncol 2005;77:25-31. (Pubitemid 41503385)
11. Goldner G, Bombosch V, Geinitz H, et al. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from prospective Austian-German multicenter phase II trial. Strahlenther Onkol 2009;185:94-100.
12. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994;193:703.
13. Jacob V, Bayer W, Astner S, et al. A planning comparison of dynamic IMRT for different collimator leaf thicknesses with helical Tomotherapy and RapidArc for prostate and head and neck tumors. Strahlenther Onkol 2010;186:502-10.
14. Janssen S, Karsten JH. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. Strahlenther Onkol 2010;186:526-8.
15. Jeong, CW, Park HK, Hong, SK, et al. Comparison of prostate volume measured by transrectal ultrasonography and MRI with the actual prostate volume measured after radical prostatectomy. Urol Int 2008;81:179-85.
16. Kagawa K, Lee R, Schultheiss T, et al. Initial clinical assessment of CT-MRI Image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997;38:319-25. (Pubitemid 27318647)
17. Katcher J, Kupelian A, Zippe C, et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 1997;37:871-6. (Pubitemid 27181321)
18. Kestin L, Goldstein N, Vicini F, et al. Treatment of prostate cancer with radiotherapy: should the seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 2002;54:686-97.
19. Mah D, Steckner M, Hanlon A, et al. MRI simulation: effect of gradient distortions on three-dimensional prostate Cancer plans. Int J Radiat Oncol Biol Phys 2002;53:757-65. (Pubitemid 34626517)
20. Mizowaki T, Nagata Y, Okajiama K, et al. Reproducibility of geometrical distortion in magnetic resonance imaging based on phantom studies. Radiother. Oncol 2000;57:237-42.
21. Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205-12.
22. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51. (Pubitemid 27208886)
23. Perrotti M, Kaufman RP, Jennings TA, et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: Is it accurate? Urology 1996;156:106-9. (Pubitemid 26185650)
24. Rasch C, Barillot I, Remeijer P, et al. Definition of the prostate in CT and MRI: a multiobserver study. Int J Radiat Oncol Biol Phys 1999;43:57-66. (Pubitemid 29065832)
25. Ren J, Huan Y, Wang H, et al. Seminal vesicle invasion in prostate cancer: prediction with combined T2-weighted and diffusion-weighted MR imaging. Eur Radiol 2009;19(10):2481-6.
26. Roach III M. Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate spezific antigen. J Urology 1993;150:1923-4.
27. Roach III M, Faillace P, Malfatti C, et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-8. (Pubitemid 26279773)
28. Sala E, Akin O, Moskowitz C, et al. Endorectal MR imaging in evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006;238:929-37. (Pubitemid 43289924)
29. Sannazzari GL, Ragona R, Ruo MG, et al. CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. British J Radiology 2002;75:603-7. (Pubitemid 34830612)
30. Schiebler M, Schnall M, Pollack H, et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 1993;189:339.
31. Tempany M, Zhou X, Zerhouni E, et al. Staging of prostate cancer: results of radiology diagnostic oncology group project. Comparison of three MR imaging techniques. Radiology 1994;192:47.
32. Wang L, Zhang J, Schwartz LH, et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007;188:99-104. (Pubitemid 46012495)
33. Zelefsky, MJ, Fuks Z , Hunt M, et al. High- dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6. (Pubitemid 34787844)